DMK Pharma Says Contaminated Injectors Led To Ch. 11 Filing

By Yun Park · May 31, 2024, 2:51 PM EDT

Drugmaker DMK Pharmaceuticals Corp. has filed an adversary complaint in Delaware bankruptcy court, saying its epinephrine-injector supplier failed to maintain contaminant-free manufacturing facilities sold to the debtor, which caused one of...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

DMK Pharmaceuticals has applied for Chapter 11 protection in Delaware, citing recent clinical trial failures and product recalls, as well as the government's allegation that a subsidiary engaged in criminal activities, as reasons for seeking bankruptcy relief.

Case Number

24-10153

Judge

Mary F. Walrath

Venue

U.S. Bankruptcy Court for the District of Delaware

Capital Structure

Total Liabilities:

$13.9M

View Full Scorecard

Documents

Complaint